Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Other 1Classical hematology 1

Conditions

Pain, Intractable 1Neoplasms 1Mucositis 1Leukemia 1Bone Marrow Failure Disorders 1Anemia, Aplastic 1

Interventions

Paclitaxel 20Gemcitabine 16Dexamethasone 16Bevacizumab 16Docetaxel 15Oxaliplatin 14Cyclophosphamide 13Carboplatin 12Capecitabine 12Sorafenib 11Fluorouracil 11Leucovorin 10Cisplatin 10pembrolizumab 9Pemetrexed 9Epoetin Alfa 9venetoclax 8Prednisone 8Fentanyl 8Drug Therapy 8Doxorubicin 8atezolizumab 7Rivaroxaban 7Rituximab 7Darbepoetin alfa 7Anastrozole 7Panitumumab 6Ondansetron 6Morphine 6Irinotecan 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Neoplasms × Passive Cutaneous Anaphylaxis × Clear all
NCT06940570 2025-10-23

MATCH

University of Texas Southwestern Medical Center

Phase 3 Suspended
60 enrolled
Classical hematologyOtherOther hematologic neoplasm

Bone Marrow Failure Disorders, Anemia, Aplastic, Leukemia, Neoplasms, Pain, Intractable, Mucositis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡